iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
Twice Daily Telaprevir in Combination With Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Liver Transplant Recipients: Interim Pharmacokinetics of the REFRESH Study
 
 
  Reported by Jules Levin
 
Presented at the American Transplant Congress, May 1822, 2013, in Seattle, Washington
 
Hugo E. Vargas, MD1; Yang Dai, PhD2; Kimberly A. Brown, MD3; Mark W. Russo, MD4; Eric Yoshida, MD5; Robert J. Fontana, MD6; Josh Levitsky, MD7; Raymond Rubin, MD2; Varun Garg, PhD2; Robert S. Brown, MD, MPH8 1Mayo Clinic, Scottsdale, AZ, USA; 2Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA; 3Henry Ford Hospital, Detroit, MI, USA; 4Carolinas Medical Center, Charlotte, NC, USA; 5University of British Columbia, Vancouver, British Columbia, CAN; 6University of Michigan, Ann Arbor, MI, USA; 7Northwestern University, Chicago, IL, USA; 8Columbia University, New York, NY, USA

HCV1.gif

HCV2.gif

HCV3.gif

HCV4.gif

HCV5.gif

HCV6.gif

HCV7.gif

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org